Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273494|
Recruitment Status : Unknown
Verified May 2008 by Rigshospitalet, Denmark.
Recruitment status was: Recruiting
First Posted : January 9, 2006
Last Update Posted : May 22, 2008
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease.
Patients are randomised to surgery or not.
|Condition or disease||Intervention/treatment||Phase|
|Non-Small Cell Lung Cancer||Procedure: Surgery||Phase 3|
Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation.
Endpoint is survival.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||406 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).|
|Study Start Date :||January 1998|
|Study Completion Date :||January 2008|
- time to progression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273494
|Contact: Jens B. Sorensen, MDemail@example.com|
|Dept. Oncology, Rigshospitalet||Recruiting|
|Copenhagen, Denmark, 2100|
|Contact: Jens B. Sorensen, MD 35454372 firstname.lastname@example.org|
|Contact: Jens B. Sorensen, MD 35454372 ext email@example.com|
|Principal Investigator: Jens B. Sorensen, MD|
|Study Chair:||Jens B. Sorensen, MD||Rigshospitalet, Denmark|